A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome (original) (raw)

• Lejeune, J., Gautier, M. & Turpin, R. Etude des chromosomes somatiques de neuf enfants mongoliens. C. R. Hebd. Seances Acad. Sci. 248, 1721–1722 (in French) (1959).
  CAS PubMed Google Scholar
• de Graaf, G., Buckley, F. & Skotko, B. G. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am. J. Med. Genet. A 167A, 756–767 (2015).
  PubMed Google Scholar
• Wu, J. H. & Morris, J. K. Trends in maternal age distribution and the live birth prevalence of Down's syndrome in England and Wales: 1938–2010. Eur. J. Hum. Genet. 21, 943–947 (2013).
  PubMed PubMed Central Google Scholar
• Wu, J. H. & Morris, J. K. The population prevalence of Down's syndrome in England and Wales in 2011. Eur. J. Hum. Genet. 21, 1016–1019 (2013).
  PubMed PubMed Central Google Scholar
• Wiseman, F. K., Alford, K. A., Tybulewicz, V. L. J. & Fisher, E. M. C. Down syndrome — recent progress and future prospects. Hum. Mol. Genet. 18, R75–R83 (2009).
  CAS PubMed PubMed Central Google Scholar
• McCarron, M., McCallion, P., Reilly, E. & Mulryan, N. A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome. J. Intellect. Disabil. Res. 58, 61–70 (2014).
  CAS PubMed Google Scholar
• Zigman, W. B., Schupf, N., Urv, T., Zigman, A. & Silverman, W. Incidence and temporal patterns of adaptive behavior change in adults with mental retardation. Am. J. Mental Retard. 107, 161–174 (2002).
  Google Scholar
• Hooli, B. V. et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78, 1250–1257 (2012).
  CAS PubMed PubMed Central Google Scholar
• Kasuga, K. et al. Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80, 1050–1052 (2009).
  CAS PubMed Google Scholar
• McNaughton, D. et al. Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol. Aging 33, 426.e13–426.e21 (2010).
  Google Scholar
• Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24–26 (2006).
  CAS PubMed Google Scholar
• Rovelet-Lecrux, A. et al. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry 78, 1158–1159 (2007).
  CAS PubMed PubMed Central Google Scholar
• Sleegers, K. et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129, 2977–2983 (2006).
  PubMed Google Scholar
• Swaminathan, S. et al. Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. PLoS ONE 7 e50640 (2012).
  CAS PubMed PubMed Central Google Scholar
• Thonberg, H. et al. Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient. BMC Res. Notes 4, 476 (2011).
  CAS PubMed PubMed Central Google Scholar
• Prasher, V. P. et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 43, 380–383 (1998).
  CAS PubMed Google Scholar
• Korbel, J. O. et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc. Natl Acad. Sci. USA 106, 12031–12036 (2009).
  CAS PubMed PubMed Central Google Scholar
• Fraser, J. & Mitchell, A. Kalmuc idiocy: report of a case with autopsy with notes on 62 cases. J. Mental Sci. 22, 161–169 (1876).
  Google Scholar
• Strydom, A. et al. Dementia in older adults with intellectual disabilities — epidemiology, presentation, and diagnosis. J. Intellect. Disabil. 7, 96–110 (2010).
  Google Scholar
• Tyrrell, J. et al. Dementia in people with Down's syndrome. Int. J. Geriatr. Psychiatry 16, 1168–1174 (2001).
  CAS PubMed Google Scholar
• Coppus, A. et al. Dementia and mortality in persons with Down's syndrome. J. Intellect. Disabil. Res. 50, 768–777 (2006).
  CAS PubMed Google Scholar
• Visser, F. E., Aldenkamp, A. P., vanHuffelen, A. C., Kuilman, M. & Overweg, J. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am. J. Mental Retard. 101, 400–412 (1997).
  CAS Google Scholar
• Krinsky-McHale, S. J. et al. Successful aging in a 70-year-old man with Down syndrome: a case study. Intellect. Dev. Disabil. 46, 215–228 (2008).
  PubMed Google Scholar
• Coppus, A. M. W. et al. Early age at menopause is associated with increased risk of Dementia and mortality in women with Down syndrome. J. Alzheimers Dis. 19, 545–550 (2010).
  PubMed Google Scholar
• Schupf, N. et al. Onset of dementia is associated with age at menopause in women with Down's syndrome. Ann. Neurol. 54, 433–438 (2003).
  PubMed Google Scholar
• Cosgrave, M. P., Tyrrell, J., McCarron, M., Gill, M. & Lawlor, B. A. Age at onset of dementia and age of menopause in women with Down's syndrome. J. Intellect. Disabil. Res. 43, 461–465 (1999).
  PubMed Google Scholar
• Draheim, C. C., Geijer, J. R. & Dengel, D. R. Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome. Am. J. Cardiol. 106, 1512–1516 (2010).
  PubMed Google Scholar
• Zigman, W. B. et al. Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome. Neurosci. Lett. 416, 279–284 (2007).
  CAS PubMed PubMed Central Google Scholar
• Ylaherttuala, S., Luoma, J., Nikkari, T. & Kivimaki, T. Downs-syndrome and atherosclerosis. Atherosclerosis 76, 269–272 (1989).
  CAS Google Scholar
• van de Louw, J., Vorstenbosch, R., Vinck, L., Penning, C. & Evenhuis, H. Prevalence of hypertension in adults with intellectual disability in the Netherlands. J. Intellect. Disabil. Res. 53, 78–84 (2009).
  CAS PubMed Google Scholar
• Stampfer, M. J. Cardiovascular disease and Alzheimer's disease: common links. J. Internal Med. 260, 211–223 (2006).
  CAS PubMed Google Scholar
• Stern, Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 11, 1006–1012 (2012).
  PubMed PubMed Central Google Scholar
• Zigman, W. B. et al. Alzheimer's disease in adults with Down syndrome. Int. Rev. Res. Ment. Retard. 36, 103–145 (2008).
  PubMed PubMed Central Google Scholar
• Margallo-Lana, M. L. et al. Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J. Intellect. Disabil. Res. 51, 463–477 (2007).
  CAS PubMed Google Scholar
• Devenny, D. A., Krinsky-McHale, S. J., Sersen, G. & Silverman, W. P. Sequence of cognitive decline in dementia in adults with Down's syndrome. J. Intellect. Disabil. Res. 44, 654–665 (2000).
  PubMed Google Scholar
• Devenny, D. A., Zimmerli, E. J., Kittler, P. & Krinsky-McHale, S. J. Cued recall in early-stage dementia in adults with Down's syndrome. J. Intellect. Disabil. Res. 46, 472–483 (2002).
  CAS PubMed Google Scholar
• Krinsky-McHale, S. J., Devenny, D. A. & Silverman, W. P. Changes in explicit memory associated with early dementia in adults with Down's syndrome. J. Intellect. Disabil. Res. 46, 198–208 (2002).
  CAS PubMed Google Scholar
• Adams, D. & Oliver, C. The relationship between acquired impairments of executive function and behaviour change in adults with Down syndrome. J. Intellect. Disabil. Res. 54, 393–405 (2010).
  CAS PubMed Google Scholar
• Ball, S. L. et al. Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study. Int. J. Geriatr. Psychiatry 21, 661–673 (2006).
  PubMed Google Scholar
• Ball, S. L., Holland, A. J., Treppner, P., Watson, P. C. & Huppert, F. A. Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities. Br. J. Clin. Psychol. 47, 1–29 (2008).
  PubMed Google Scholar
• Holland, A. J., Hon, J., Huppert, F. A. & Stevens, F. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J. Intellect. Disabil. Res. 44, 138–146 (2000).
  PubMed Google Scholar
• Oliver, C., Kalsy, S., McQuillan, S. & Hall, S. Behavioural excesses and deficits associated with dementia in adults who have Down syndrome. J. Appl. Res. Intellect. Disabil. 24, 208–216 (2011).
  Google Scholar
• Nelson, L. D., Orme, D., Osann, K. & Lott, I. T. Neurological changes and emotional functioning in adults with Down Syndrome. J. Intellect. Disabil. Res. 45, 450–456 (2001).
  CAS PubMed Google Scholar
• Powell, D. et al. Frontal white matter integrity in adults with Down syndrome with and without dementia. Neurobiol. Aging 35, 1562–1569 (2014).
  PubMed PubMed Central Google Scholar
• Jennings, D. et al. Age dependence of brain ß-amyloid deposition in Down syndrome: an [18F]florbetaben PET study. Neurology 84, 500–507 (2015).
  CAS PubMed Google Scholar
• Masters, M. C., Morris, J. C. & Roe, C. M. 'Noncognitive' symptoms of early Alzheimer disease: a longitudinal analysis. Neurology 84, 617–622 (2015).
  CAS PubMed PubMed Central Google Scholar
• Wallon, D. et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J. Alzheimers Dis. 30, 847–856 (2012).
  CAS PubMed Google Scholar
• De Simone, R., Puig, X. S., Gélisse, P., Crespel, A. & Genton, P. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer's disease in Down syndrome. Seizure 19, 383–389 (2010).
  PubMed Google Scholar
• Moller, J. C., Hamer, H. M., Oertel, W. H. & Rosenow, F. Late-onset myoclonic epilepsy in Down's syndrome (LOMEDS). Seizure 10, 303–305 (2001).
  CAS PubMed Google Scholar
• d'Orsi, G. & Specchio, L. M. Progressive myoclonus epilepsy in Down syndrome patients with dementia. J. Neurol. 261, 1584–1597 (2014).
  CAS PubMed Google Scholar
• Friedman, D., Honig, L. S. & Scarmeas, N. Seizures and epilepsy in Alzheimer's disease. CNS Neurosci. Ther. 18, 285–294 (2012).
  PubMed Google Scholar
• Vossel, K. A. et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 70, 1158–1166 (2013).
  PubMed PubMed Central Google Scholar
• Irizarry, M. C. et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch. Neurol. 69, 368–372 (2012).
  PubMed PubMed Central Google Scholar
• Lott, I. T. et al. Down syndrome and dementia: seizures and cognitive decline. J. Alzheimers Dis. 29, 177–185 (2012).
  PubMed PubMed Central Google Scholar
• Crayton, L., Oliver, C., Holland, A., Bradbury, J. & Hall, S. The neuropsychological assessment of age related cognitive deficits in adults with Down's syndrome. J. Appl. Res. Intellect. Disabil. 11, 255–272 (1998).
  Google Scholar
• Dalton, A. J., Mehta, P. D., Fedor, B. L. & Patti, P. J. Cognitive changes in memory precede those in praxis in aging persons with Down syndrome. J. Intellect. Dev. Disabil. 24, 169–187 (1999).
  Google Scholar
• Struwe, F. Histopathologische Untersuchungen über Entstehung und Wesen der senile Plaques. Z. Gesamte Neurol. Psy. 122, 291–307 (in German) (1929).
  Google Scholar
• Glenner, G. G. & Wong, C. W. Alzheimer's disease and Downs syndrome — sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131–1135 (1984).
  CAS PubMed Google Scholar
• Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704–706 (1991).
  CAS PubMed Google Scholar
• Hardy, J. A. & Higgins, G. A. Alzheimer's disease — the amyloid cascade hypothesis. Science 256, 184–185 (1992).
  CAS PubMed Google Scholar
• Goedert, M., Spillantini, M. G., Cairns, N. J. & Crowther, R. A. Tau proteins of Alzheimer paired helical filaments — abnormal phosphorylation of all 6 brain isoforms. Neuron 8, 159–168 (1992).
  CAS PubMed Google Scholar
• Mann, D. M. A. Alzheimer's disease and Down's syndrome. Histopathology 13, 125–137 (1988).
  CAS PubMed Google Scholar
• Wisniewski, H. M. & Rabe, A. Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome. Ann. NY Acad. Sci. 477, 247–260 (1986).
  CAS PubMed Google Scholar
• Mann, D. M. A. The pathological association between Down syndrome and Alzheimer's disease. Mech. Ageing Dev. 43, 99–136 (1988).
  CAS PubMed Google Scholar
• Leverenz, J. B. & Raskind, M. A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol. 150, 296–304 (1998).
  CAS PubMed Google Scholar
• Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
  CAS PubMed Google Scholar
• Egensperger, R. et al. Reverse relationship between β-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease. Acta Neuropathol. 97, 113–118 (1999).
  CAS PubMed Google Scholar
• Mann, D. M. A., Yates, P. O., Marcyniuk, B. & Ravindra, C. R. Loss of neurons from cortical and subcortical areas in Down's syndrome patients at middle-age — quantitative comparisons with younger Down's patients and patients with Alzheimer's disease. J. Neurol. Sci. 80, 79–89 (1987).
  CAS PubMed Google Scholar
• Allsop, D., Kidd, M., Landon, M. & Tomlinson, A. Isolated senile plaque cores in Alzheimer's disease and Down's syndrome show differences in morphology. J. Neurol. Neurosurg. Psychiatry 49, 886–892 (1986).
  CAS PubMed PubMed Central Google Scholar
• Armstrong, R. A. Size frequency distributions of β-amyloid (4β) deposits: a comparative study of four neurodegenerative disorders. Folia Neuropathol. 50, 240–249 (2012).
  CAS PubMed Google Scholar
• Bero, A. W. et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat. Neurosci. 14, 750–756 (2011).
  CAS PubMed PubMed Central Google Scholar
• Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E. & Troncoso, J. C. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125, 489–492 (2001).
  CAS PubMed Google Scholar
• Hirayama, A., Horikoshi, Y., Maeda, M., Ito, M. & Takashima, S. Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome. Brain Dev. 25, 180–185 (2003).
  PubMed Google Scholar
• Iwatsubo, T., Mann, D. M. A., Odaka, A., Suzuki, N. & Ihara, Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann. Neurol. 37, 294–299 (1995).
  CAS PubMed Google Scholar
• Mori, C. et al. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid 9, 88–102 (2002).
  CAS PubMed Google Scholar
• Wegiel, J. et al. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol. 113, 389–402 (2007).
  CAS PubMed PubMed Central Google Scholar
• Wisniewski, K. E., Wisniewski, H. M. & Wen, G. Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17, 278–282 (1985).
  CAS PubMed Google Scholar
• Wisniewski, K. E., Dalton, A. J., Mclachlan, D. R. C., Wen, G. Y. & Wisniewski, H. M. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 35, 957–961 (1985).
  CAS PubMed Google Scholar
• Burger, P. C. & Vogel, F. S. The development of pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am. J. Pathol. 73, 457–476 (1973).
  CAS PubMed PubMed Central Google Scholar
• Lemere, C. A. et al. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16–32 (1996).
  CAS PubMed Google Scholar
• Ball, M. J. & Nuttall, K. Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in Down syndrome: quantitative comparison with Alzheimer dementia. Ann. Neurol. 7, 462–465 (1980).
  CAS PubMed Google Scholar
• Mann, D. M. A. & Esiri, M. M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 89, 169–179 (1989).
  CAS PubMed Google Scholar
• Whalley, L. J. The dementia of Down's syndrome and its relevance to etiological studies of Alzheimer's disease. Ann. NY Acad. Sci. 396, 39–53 (1982).
  CAS PubMed Google Scholar
• Ropper, A. H. & Williams, R. S. Relationship between plaques, tangles, and dementia in Down syndrome. Neurology 30, 639–644 (1980).
  CAS PubMed Google Scholar
• Godridge, H., Reynolds, G. P., Czudek, C., Calcutt, N. A. & Benton, M. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J. Neurol. Neurosurg. Psychiatry 50, 775–778 (1987).
  CAS PubMed PubMed Central Google Scholar
• Murphy, G. M. et al. Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease. Brain Res. 537, 102–108 (1990).
  CAS PubMed Google Scholar
• Motte, J. & Williams, R. S. Age-related-changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol. 77, 535–546 (1989).
  CAS PubMed Google Scholar
• Head, E. et al. Parallel compensatory and pathological events associated with Tau pathology in middle aged individuals with Down syndrome. J. Neuropathol. Exp. Neurol. 62, 917–926 (2003).
  CAS PubMed Google Scholar
• Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).
  PubMed PubMed Central Google Scholar
• Mann, D. M. A. Cerebral amyloidosis, aging and Alzheimer's disease: a contribution from studies on Down's syndrome. Neurobiol. Aging 10, 397–399 (1989).
  CAS PubMed Google Scholar
• Evenhuis, H. M. The natural history of dementia in Down's syndrome. Arch. Neurol. 47, 263–267 (1990).
  CAS PubMed Google Scholar
• McCarron, M. O., Nicoll, J. A. R. & Graham, D. I. A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors. J. Neurol. Neurosurg. Psychiatry 65, 405–406 (1998).
  CAS PubMed PubMed Central Google Scholar
• Mendel, T., Bertrand, E., Szpak, G. M., Stepien, T. & Wierzba-Bobrowicz, T. Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome — a case report. Folia Neuropathol. 48, 206–211 (2010).
  PubMed Google Scholar
• Naito, K. S., Sekijima, Y. & Ikeda, S. I. Cerebral amyloid angiopathy-related hemorrhage in a middle-aged patient with Down's syndrome. Amyloid 15, 275–277 (2008).
  CAS PubMed Google Scholar
• Donahue, J. E., Khurana, J. S. & Adelman, L. S. Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy. Acta Neuropathol. 95, 213–216 (1998).
  CAS PubMed Google Scholar
• Handen, B. L. et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 8, 496–501 (2012).
  CAS PubMed PubMed Central Google Scholar
• Nelson, L. D. et al. Positron emission tomography of brain β-amyloid and Tau levels in adults with Down syndrome. Arch. Neurol. 68, 768–774 (2011).
  PubMed PubMed Central Google Scholar
• Matveev, S. V. et al. A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. J. Neurochem. 131, 356–368 (2014).
  CAS PubMed PubMed Central Google Scholar
• Hartley, S. L. et al. Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. Brain 137, 2556–2563 (2014).
  PubMed PubMed Central Google Scholar
• Landt, J. et al. Using positron emission tomography and carbon 11-labeled Pittsburgh compound B to image brain fibrillar β-amyloid in adults with Down syndrome safety, acceptability, and feasibility. Arch. Neurol. 68, 890–896 (2011).
  PubMed Google Scholar
• Lippa, C. F. et al. Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. Arch. Neurol. 66, 1483–1488 (2009).
  PubMed PubMed Central Google Scholar
• Davidson, Y. S. et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 122, 703–713 (2011).
  PubMed Google Scholar
• Gibb, W. R. G., Mountjoy, C. Q., Mann, D. M. A. & Lees, A. J. A pathological study of the association between Lewy body disease and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 52, 701–708 (1989).
  CAS PubMed PubMed Central Google Scholar
• Prasher, V. P., Airuehia, E. & Carey, M. The first confirmed case of Down syndrome with dementia with Lewy bodies. J. Appl. Res. Intellect. Disabil. 23, 296–300 (2010).
  Google Scholar
• Cataldo, A. M. et al. Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome. Neurobiol. Aging 25, 1263–1272 (2004).
  CAS PubMed Google Scholar
• Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45, 1452–1458 (2013).
  CAS PubMed PubMed Central Google Scholar
• Hooli, B. V. et al. Rare autosomal copy number variations in early-onset familial Alzheimer's disease. Mol. Psychiatry 19, 676–681 (2014).
  CAS PubMed Google Scholar
• Llado, A. et al. Large APP locus duplication in a sporadic case of cerebral haemorrhage. Neurogenetics 15, 145–149 (2014).
  PubMed Google Scholar
• Cabrejo, L. et al. Phenotype associated with APP duplication in five families. Brain 129, 2966–2976 (2006).
  PubMed Google Scholar
• Noebels, J. A perfect storm: converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia 52, 39–46 (2011).
  PubMed PubMed Central Google Scholar
• Griffiths-Jones, S. The microRNA registry. Nucleic Acids Res. 32, D109–D111 (2004).
  CAS PubMed PubMed Central Google Scholar
• Vilardell, M. et al. Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 12, 229 (2011).
  PubMed PubMed Central Google Scholar
• Letourneau, A. et al. Domains of genome-wide gene expression dysregulation in Down's syndrome. Nature 508, 345–350 (2014).
  CAS PubMed Google Scholar
• Horvath, S. et al. Accelerated epigenetic aging in Down syndrome. Aging Cell 14, 491–495 (2015).
  CAS PubMed PubMed Central Google Scholar
• Cheon, M. S., Dierssen, M., Kim, S. H. & Lubec, G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids 35, 339–343 (2008).
  CAS PubMed Google Scholar
• Choi, J. H. K. et al. Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model. J. Neurochem. 110, 1818–1827 (2009).
  CAS PubMed PubMed Central Google Scholar
• Seo, H. & Isacson, O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp. Neurol. 193, 469–480 (2005).
  CAS PubMed Google Scholar
• Teller, J. K. et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2, 93–95 (1996).
  CAS PubMed Google Scholar
• Busciglio, J. et al. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677–688 (2002).
  CAS PubMed Google Scholar
• Govoni, S. et al. Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation. Neurology 47, 1069–1075 (1996).
  CAS PubMed Google Scholar
• Murray, A., Letourneau, A. & Canzonetta, C. Isogenic induced pluripotent stem cell lines from an adult with mosaic Down syndrome model accelerated neuronal ageing and neurodegeneration. Stem Cells 33, 2077–2084 (2015).
  CAS PubMed PubMed Central Google Scholar
• Shi, Y. C. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 4, 124ra29 (2012).
  PubMed PubMed Central Google Scholar
• Wolvetang, E. W. et al. The chromosome 21 transcription factor ETS2 transactivates the β-APP promoter: implications for Down syndrome. Biochim. Biophys. Acta 1628, 105–110 (2003).
  CAS PubMed Google Scholar
• Dorval, V., Mazzella, M. J., Mathews, P. M., Hay, R. T. & Fraser, P. E. Modulation of Aβ generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem. J. 404, 309–316 (2007).
  CAS PubMed PubMed Central Google Scholar
• Li, Y. H. et al. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl Acad. Sci. USA 100, 259–264 (2003).
  CAS PubMed Google Scholar
• Ryoo, S. R. et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J. Neurochem. 104, 1333–1344 (2008).
  CAS PubMed Google Scholar
• Wang, X. et al. Sorting nexin 27 regulates Aβ production through modulating γ-secretase activity. Cell Rep. 9, 1023–1033 (2014).
  CAS PubMed PubMed Central Google Scholar
• Mok, K. Y. et al. Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. Neurobiol. Aging 35, 1513.e1–1513.e5 (2014).
  CAS Google Scholar
• Sun, X. L., He, G. Q. & Song, W. H. BACE2, as a novel APP θ-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 20, 1369–1376 (2006).
  CAS PubMed Google Scholar
• Azkona, G., Levannon, D., Groner, Y. & Dierssen, M. In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. Amino Acids 39, 1571–1580 (2010).
  CAS PubMed Google Scholar
• Holler, C. J. et al. BACE2 expression increases in human neurodegenerative disease. Am. J. Pathol. 180, 337–350 (2012).
  CAS PubMed PubMed Central Google Scholar
• Patel, A. et al. Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome. Neurosci. Lett. 487, 144–148 (2011).
  CAS PubMed Google Scholar
• Prasher, V. P. et al. Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome. Int. J. Geriatr. Psychiatry 23, 1134–1140 (2008).
  CAS PubMed PubMed Central Google Scholar
• Deb, S. et al. APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. Br. J. Psychiatry 176, 468–472 (2000).
  CAS PubMed Google Scholar
• Coppus, A. M. W. et al. The impact of apolipoprotein E on dementia in persons with Down's syndrome. Neurobiol. Aging 29, 828–835 (2008).
  CAS PubMed Google Scholar
• Schupf, N. et al. Onset of dementia is associated with apolipoprotein E epsilon 4 in Down's syndrome. Ann. Neurol. 40, 799–801 (1996).
  CAS PubMed Google Scholar
• Hyman, B. T. et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc. Natl Acad. Sci. USA 92, 3586–3590 (1995).
  CAS PubMed PubMed Central Google Scholar
• Royston, M. C. et al. Apolipoprotein-e epsilon-2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport 5, 2583–2585 (1994).
  CAS PubMed Google Scholar
• Jones, E. L. et al. Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. Neurobiol. Aging 34, 2441.e1–2441.e5 (2013).
  CAS Google Scholar
• Lee, J. H. et al. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome. Neurosci. Lett. 425, 105–109 (2007).
  CAS PubMed PubMed Central Google Scholar
• Salehi, A. et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29–42 (2006).
  CAS PubMed Google Scholar
• Torroja, L., Chu, H., Kotovsky, I. & White, K. Neuronal overexpression of APPL, the Drosophila homologue of the amyloid precursor protein (APP), disrupts axonal transport. Curr. Biol. 9, 489–492 (1999).
  CAS PubMed Google Scholar
• Jiang, Y. et al. Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl Acad. Sci. USA 107, 1630–1635 (2010).
  CAS PubMed Google Scholar
• Barbosa, S., Pratte, D., Schwarz, H., Pipkorn, R. & Singer-Kruger, B. Oligomeric Dop1p is part of the endosomal Neo1p–Ysl2p–Arl1p membrane remodeling complex. Traffic 11, 1092–1106 (2010).
  CAS PubMed Google Scholar
• Swaminathan, S. et al. Analysis of copy number variation in Alzheimer's disease: the NIA-LOAD/NCRAD family study. Curr. Alzheimer Res. 9, 801–814 (2012).
  CAS PubMed PubMed Central Google Scholar
• Chapman, J. et al. A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk. Hum. Mol. Genet. 22, 816–824 (2013).
  CAS PubMed Google Scholar
• Yang, D. S. et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 134, 258–277 (2011).
  PubMed Google Scholar
• Cossec, J. C. et al. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum. Mol. Genet. 21, 3156–3172 (2012).
  CAS PubMed PubMed Central Google Scholar
• McIntire, L. B. J. et al. Reduction of synaptojanin 1 ameliorates synaptic and behavioral impairments in a mouse model of Alzheimer's disease. J. Neurosci. 32, 15271–15276 (2012).
  CAS PubMed PubMed Central Google Scholar
• Zhu, L. et al. Reduction of synaptojanin 1 accelerates Aβ clearance and attenuates cognitive deterioration in an Alzheimer mouse model. J. Biol. Chem. 288, 32050–32063 (2013).
  CAS PubMed PubMed Central Google Scholar
• Busciglio, J. & Yankner, B. A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378, 776–779 (1995).
  CAS PubMed Google Scholar
• Shukkur, E. A. et al. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet. 15, 2752–2762 (2006).
  CAS PubMed Google Scholar
• Phillips, A. C. et al. Defective mitochondrial function in vivo in skeletal muscle in adults with Down's syndrome: a 31P-MRS study. PLoS ONE 8, e84031 (2013).
  PubMed PubMed Central Google Scholar
• Weick, J. P. et al. Deficits in human trisomy 21 iPSCs and neurons. Proc. Natl Acad. Sci. USA 110, 9962–9967 (2013).
  CAS PubMed PubMed Central Google Scholar
• Zigman, W. B. Atypical aging in Down syndrome. Dev. Disabil. Res. Rev. 18, 51–67 (2013).
  PubMed Google Scholar
• Picard, M. & Mcewen, B. S. Mitochondria impact brain function and cognition. Proc. Natl Acad. Sci. USA 111, 7–8 (2014).
  CAS PubMed Google Scholar
• Lott, I. T. et al. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am. J. Med. Genet. A 155A, 1939–1948 (2011).
  PubMed PubMed Central Google Scholar
• Carlson, G. A. et al. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum. Mol. Genet. 6, 1951–1959 (1997).
  CAS PubMed Google Scholar
• Murakami, K. et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. J. Biol. Chem. 286, 44557–44568 (2011).
  CAS PubMed PubMed Central Google Scholar
• Zis, P., Dickinson, M., Shende, S., Walker, Z. & Strydom, A. Oxidative stress and memory decline in adults with Down syndrome: longitudinal study. J. Alzheimers Dis. 31, 277–283 (2012).
  CAS PubMed Google Scholar
• deHaan, J. B. et al. Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum. Mol. Genet. 5, 283–292 (1996).
  CAS Google Scholar
• Anderson, J. S. et al. Abnormal brain synchrony in Down syndrome. Neuroimage Clin. 2, 703–715 (2013).
  PubMed PubMed Central Google Scholar
• Belichenko, P. V. et al. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome. J. Comp. Neurol. 512, 453–466 (2008).
  Google Scholar
• Fernandez, F. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411–413 (2007).
  CAS PubMed Google Scholar
• Schmidt-Sidor, B., Wisniewski, K. E., Shepard, T. H. & Sersen, E. A. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin. Neuropathol. 9, 181–190 (1990).
  CAS PubMed Google Scholar
• Takashima, S., Becker, L. E., Armstrong, D. L. & Chan, F. Abnormal neuronal development in the visual cortex of the human fetus and infant with down's syndrome. A quantitative and qualitative Golgi study. Brain Res. 225, 1–21 (1981).
  CAS PubMed Google Scholar
• Adorno, M. et al. Usp16 contributes to somatic stem-cell defects in Down's syndrome. Nature 501, 380–384 (2013).
  CAS PubMed PubMed Central Google Scholar
• Canzonetta, C. et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am. J. Hum. Genet. 83, 388–400 (2008).
  CAS PubMed PubMed Central Google Scholar
• Hibaoui, Y. et al. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. EMBO Mol. Med. 6, 259–277 (2014).
  CAS PubMed Google Scholar
• Chang, K. T. & Min, K. T. Upregulation of three Drosophila homologs of human chromosome 21 genes alters synaptic function: implications for Down syndrome. Proc. Natl Acad. Sci. USA 106, 17117–17122 (2009).
  CAS PubMed PubMed Central Google Scholar
• Cvetkovska, V., Hibbert, A. D., Emran, F. & Chen, B. E. Overexpression of Down syndrome cell adhesion molecule impairs precise synaptic targeting. Nat. Neurosci. 16, 677–682 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wang, B. P. et al. The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons. J. Neurosci. 34, 13314–13325 (2014).
  CAS PubMed PubMed Central Google Scholar
• Nicolas, M. & Hassan, B. A. Amyloid precursor protein and neural development. Development 141, 2543–2548 (2014).
  CAS PubMed Google Scholar
• Ma'ayan, A., Gardiner, K. J. & Iyengar, R. The cognitive phenotype of Down syndrome: insights from intracellular network analysis. NeuroRx 3, 396–406 (2006).
  PubMed PubMed Central Google Scholar
• Drewes, G. et al. Dephosphorylation of Tau-protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. Febs Lett. 336, 425–432 (1993).
  CAS PubMed Google Scholar
• Liu, F. et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 22, 3224–3233 (2008).
  CAS PubMed PubMed Central Google Scholar
• Woods, Y. L. et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355, 609–615 (2001).
  CAS PubMed PubMed Central Google Scholar
• Dowjat, W. K. et al. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 413, 77–81 (2007).
  CAS PubMed Google Scholar
• Shi, J. et al. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of Tau in Down syndrome. J. Biol. Chem. 283, 28660–28669 (2008).
  CAS PubMed PubMed Central Google Scholar
• Wegiel, J. et al. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat Tau protein in Down syndrome. J. Neuropathol. Exp. Neurol. 70, 36–50 (2011).
  CAS PubMed Google Scholar
• Moore, S. et al. APP metabolism regulates Tau protestasis in human cerebral cortex neurons. Cell Rep. 11, 689–696 (2015).
  CAS PubMed PubMed Central Google Scholar
• Lu, T. et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 507, 448–454 (2014).
  CAS PubMed PubMed Central Google Scholar
• Kimura, R. et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease. Hum. Mol. Genet. 16, 15–23 (2007).
  CAS PubMed Google Scholar
• Vazquez-Higuera, J. L. et al. DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort. BMC Med. Genet. 10, 129 (2009).
  PubMed PubMed Central Google Scholar
• Cooper, S. A. et al. Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial. Trials 15, 202 (2014).
  PubMed PubMed Central Google Scholar
• Phillips, M. C. Molecular mechanisms of cellular cholesterol efflux. J. Biol. Chem. 289, 24020–24029 (2014).
  CAS PubMed PubMed Central Google Scholar
• Kim, W. S. et al. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-β peptide generation. J. Biol. Chem. 282, 2851–2861 (2007).
  CAS PubMed Google Scholar
• Tansley, G. H. et al. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of β-amyloid precursor protein. J. Lipid Res. 48, 1022–1034 (2007).
  CAS PubMed Google Scholar
• Burgess, B. L. et al. ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 49, 1254–1267 (2008).
  CAS PubMed Google Scholar
• Perry, V. H. & Holmes, C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 10, 217–224 (2014).
  CAS PubMed Google Scholar
• Wilcock, D. M. & Griffin, W. S. T. Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J. Neuroinflammation 10, 84 (2013).
  CAS PubMed PubMed Central Google Scholar
• Griffin, W. S. T. et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl Acad. Sci. USA 86, 7611–7615 (1989).
  CAS PubMed PubMed Central Google Scholar
• Naude, P. J. W. et al. Serum NGAL is associated with distinct plasma amyloid-β peptides according to the clinical diagnosis of dementia in Down syndrome. J. Alzheimers Dis. 45, 733–743 (2015).
  CAS PubMed Google Scholar
• Mann, D. M. A. et al. Microglial cells and amyloid-β protein (A) deposition — association with Aβ40-containing plaques. Acta Neuropathol. 90, 472–477 (1995).
  CAS PubMed Google Scholar
• Xue, Q. S. & Streit, W. J. Microglial pathology in Down syndrome. Acta Neuropathol. 122, 455–466 (2011).
  CAS PubMed Google Scholar
• Sheng, J. G., Mrak, R. E. & Griffin, W. S. T. S100β protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J. Neurosci. Res. 39, 398–404 (1994).
  CAS PubMed Google Scholar
• Mori, T. et al. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 58, 300–314 (2010).
  PubMed PubMed Central Google Scholar
• Esposito, G. et al. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J. Cell. Mol. Med. 12, 914–927 (2008).
  CAS PubMed PubMed Central Google Scholar
• Chen, C. et al. Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat. Commun. 5, 4430 (2014).
  CAS PubMed Google Scholar
• Mills, S. M. et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev. Neurol. 169, 737–743 (2013).
  CAS PubMed Google Scholar
• Bothwell, M. & Giniger, E. Alzheimer's disease: neurodevelopment converges with neurodegeneration. Cell 102, 271–273 (2000).
  CAS PubMed Google Scholar
• Purro, S. A., Galli, S. & Salinas, P. C. Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. J. Mol. Cell Biol. 6, 75–80 (2014).
  CAS PubMed PubMed Central Google Scholar
• Karmiloff-Smith, A. et al. Genetic and environmental vulnerabilities in children with neurodevelopmental disorders. Proc. Natl Acad. Sci. USA 109, 17261–17265 (2012).
  CAS PubMed PubMed Central Google Scholar
• Moran, P. M., Higgins, L. S., Cordell, B. & Moser, P. C. Age-related learning-deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc. Natl Acad. Sci. USA 92, 5341–5345 (1995).
  CAS PubMed PubMed Central Google Scholar
• Yamaguchi, F. et al. Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory. Neuroreport 2, 781–784 (1991).
  CAS PubMed Google Scholar
• Mucke, L. et al. High-level neuronal expression of Aβ1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058 (2000).
  CAS PubMed PubMed Central Google Scholar
• Balducci, C. & Forloni, G. A.P. P. Transgenic mice: their use and limitations. Neuromolecular Med. 13, 117–137 (2011).
  CAS PubMed Google Scholar
• Brault, V., Pereira, P., Duchon, A. & Herault, Y. Modeling chromosomes in mouse to explore the function of genes, genomic disorders, and chromosomal organization. PLoS Genet. 2, e86 (2006).
  PubMed PubMed Central Google Scholar
• Park, I. H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877–886 (2008).
  CAS PubMed PubMed Central Google Scholar
• Li, L. B. et al. Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 11, 615–619 (2012).
  CAS PubMed PubMed Central Google Scholar
• Jiang, J. et al. Translating dosage compensation to trisomy 21. Nature 500, 296–300 (2013).
  CAS PubMed PubMed Central Google Scholar
• Chang, C. Y. et al. _N_-butylidenephthalide attenuates Alzheimer's disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons. Sci. Rep. 5, 8744 (2015).
  CAS PubMed PubMed Central Google Scholar